213 related articles for article (PubMed ID: 19679009)
1. New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
Fathi AT; Karp JE
Curr Oncol Rep; 2009 Sep; 11(5):346-52. PubMed ID: 19679009
[TBL] [Abstract][Full Text] [Related]
2. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Walsby EJ; Coles SJ; Knapper S; Burnett AK
Haematologica; 2011 Mar; 96(3):393-9. PubMed ID: 21134979
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
[TBL] [Abstract][Full Text] [Related]
4. Exploiting cellular pathways to develop new treatment strategies for AML.
Fathi AT; Grant S; Karp JE
Cancer Treat Rev; 2010 Apr; 36(2):142-50. PubMed ID: 20056334
[TBL] [Abstract][Full Text] [Related]
5. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
Garrido SM; Cooper JJ; Appelbaum FR; Willman CL; Kopecky K; Banker DE
Leuk Res; 2001 Jan; 25(1):23-32. PubMed ID: 11137557
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Ravindranath Y
Curr Opin Oncol; 2003 Jan; 15(1):23-35. PubMed ID: 12490758
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF; Karp JE
Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol.
Puty TC; Sarraf JS; Do Carmo Almeida TC; Filho VCB; de Carvalho LEW; Fonseca FLA; Adami F
Syst Rev; 2019 May; 8(1):109. PubMed ID: 31053175
[TBL] [Abstract][Full Text] [Related]
9. Problems related to resistance to cytarabine in acute myeloid leukemia.
Cros E; Jordheim L; Dumontet C; Galmarini CM
Leuk Lymphoma; 2004 Jun; 45(6):1123-32. PubMed ID: 15359991
[TBL] [Abstract][Full Text] [Related]
10. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
11. 5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine.
Galmarini CM; Cros E; Graham K; Thomas X; Mackey JR; Dumontet C
Haematologica; 2004 May; 89(5):617-9. PubMed ID: 15136231
[TBL] [Abstract][Full Text] [Related]
12. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
13. New chemotherapeutic agents in acute myeloid leukemia.
Kantarjian HM; Estey EH; Keating MA
Leukemia; 1996 Apr; 10 Suppl 1():S4-6. PubMed ID: 8618470
[TBL] [Abstract][Full Text] [Related]
14. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).
Faderl S; Ferrajoli A; Harris D; Van Q; Priebe W; Estrov Z
Anticancer Res; 2005; 25(3B):1841-50. PubMed ID: 16158916
[TBL] [Abstract][Full Text] [Related]
15. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.
Hassan HT; Zander A
Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752
[TBL] [Abstract][Full Text] [Related]
16. Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
Ravandi F
Best Pract Res Clin Haematol; 2014; 27(3-4):241-6. PubMed ID: 25455273
[TBL] [Abstract][Full Text] [Related]
17. Adult acute myeloid leukemia.
Jabbour EJ; Estey E; Kantarjian HM
Mayo Clin Proc; 2006 Feb; 81(2):247-60. PubMed ID: 16471082
[TBL] [Abstract][Full Text] [Related]
18. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
19. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
[TBL] [Abstract][Full Text] [Related]
20. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Huismans DR; Zimmermann M; Harbott J; Slater RM; Creutzig U; Veerman AJ
Blood; 2002 Nov; 100(9):3352-60. PubMed ID: 12384437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
